Proellex

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Crossover Study of the Safety and PK Properties of Proellex®

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Study to Evaluate Menses Induction in Women Administered Proellex

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

A Safety and Pharmacokinetic Study of Proellex®

Determination of the Lowest, Safe and Effective Dose of Proellex

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Open-Label Extension Study to ZPE-202